Celcuity Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CELC$67.05-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(131,705) | $(82,265) |
| Adjustments to reconcile net loss to net cash and cash equivalents used in operations: | ||
| Depreciation | 106 | 77 |
| Stock-based compensation | 12,229 | 5,148 |
| Amortization of debt issuance costs and discount | 2,466 | 1,088 |
| Payment-in-kind interest | 582 | 501 |
| Non-cash investment (income) expense | (551) | 340 |
| Non-cash operating lease expense | 62 | (2) |
| Loss on debt extinguishment | 11,477 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid clinical trial costs | 5,900 | (4,634) |
| Other current assets | (3,555) | (617) |
| Accounts payable | 1,804 | 1,840 |
| Accrued clinical trial costs | (8,884) | 4,277 |
| Accrued license milestone | (5,000) | — |
| Other accrued expenses | 4,578 | 2,182 |
| Net cash used in operating activities | (110,491) | (72,065) |
| Cash flows from investing activities: | ||
| Proceeds from maturities of investments | 165,000 | 196,738 |
| Purchases of investments | (460,650) | (106,521) |
| Purchases of property and equipment | (300) | (99) |
| Purchases of capitalized software | (121) | — |
| Net cash provided by (used in) investing activities | (296,071) | 90,118 |
| Cash flows from financing activities: | ||
| Proceeds from employee stock purchases | 798 | 253 |
| Proceeds from exercise of common stock options | 1,883 | 20 |
| Proceeds from exercise of common stock warrants | 31 | 5,600 |
| Proceeds from convertible notes, net of debt issuance costs of $17,584 and $0 during the six months ended June 30, 2026 and 2025, respectively | 557,416 | — |
| Repayment of note payable | (137,017) | — |
| Payments for debt issuance costs | — | (40) |
| Payments for secondary registration statement costs | (203) | (47) |
| Net cash provided by financing activities | 422,908 | 5,786 |
| Net change in cash and cash equivalents | 16,346 | 23,839 |
| Cash and cash equivalents: | ||
| Beginning of period | 165,703 | 22,515 |
| End of period | $182,049 | $46,354 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $9,441 | $4,799 |
| Cash paid for operating leases | $74 | $109 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Purchase of intangible assets in accrued license milestone | $50,000 | $— |
| Conversion of Term A Loan to shares of common stock | $3,368 | |
| Right-of-use asset obtained in exchange for operating lease liability | $1,150 | $— |
| Debt issuance costs included in other accrued expenses | $172 | $— |
| Exercise of common stock options pending receipt of cash proceeds | $60 | $— |
| Secondary registration statement costs included in accounts payable | $— | $47 |
| Property and equipment included in accounts payable | $— | $1 |
CELCUITY INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.